# US 8,784,840 B2 · Method for screening modulators of apoptosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,840 B2
- Document ID: US8784840B2
- Status: Granted
- Kind: B2
- Application number: 12/617,653
- Filed: 2009-11-12
- Published: 2010-03-04
- Granted: 2014-07-22
- Earliest claimed: 2003-12-02
- Assignees: The Cleveland Clinic Foundation
- Applicants: Andrei V. Gudkov
- Inventors: Andrei V. Gudkov
- Web page: https://patentgrep.com/patent/US8784840B2

## CPC

- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 38/164: {from bacteria}
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/255: Salmonella (G)
- G01N 33/502: {for testing non-proliferative effects}
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2333/4748: p53
- G01N 2333/495: Transforming growth factor [TGF]
- G01N 2500/00: Screening for compounds of potential therapeutic value
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries.

## Claims

### Claim 1

A method of treating a mammal from ionizing radiation induced apoptosis tissue damage comprising administering to a mammal in need thereof a composition comprising flagellin.

### Claim 2 (depends on 1)

The method of claim 1 wherein the composition is administered in combination with a radioprotectant.

### Claim 3 (depends on 2)

The method of claim 2 wherein the radioprotectant is an antioxidant.

### Claim 4 (depends on 3)

The method of claim 3 wherein the antioxidant is selected from the group consisting of amifostine and vitamin E.

### Claim 5 (depends on 2)

The method of claim 2 wherein the radioprotectant is a cytokine.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cytokine is stem cell factor.

### Claim 7 (depends on 1)

The method of claim 1 wherein the radiation exposure is radiation therapy for treating cancer.

### Claim 8 (depends on 1)

The method of claim 1 wherein the composition is administered prior to, together with, or after the treatment.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition is administered in combination with a growth factor.

### Claim 10 (depends on 9)

The method of claim 9, wherein the growth factor is keratinocyte growth factor.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition is administered in combination with a steroid.

### Claim 12 (depends on 11)

The method of claim 11, wherein the steroid is 5-adrostenediol.

### Claim 13 (depends on 1)

The method of claim 1, wherein the composition is administered in combination with ammonium trichloro(dioxoethylene-0-0′)tellurate.